In the recurrent tumor samples (sensible and resistant tumors) 18.3% (13 of 71) and 39.4% (28 of 71) of the samples were estrogen receptor positive based on the Immunoreactive Score and the Allred Total score, respectively. This evidence concerns the gene ESR1 and neoplasm.